Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DYN
Strong SellSinkerDyne Therapeutics, Inc. · Healthcare · United States · $4.7B · Avg Vol: $46M/d
COMPANY DESCRIPTION
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for rare, genetically driven muscle diseases. The company's proprietary FORCE (Fragment-based Oligonucleotide RNA-targeted Chimeric) platform is designed to overcome current delivery limitations, enabling precise targeting of muscle tissue. It operates as a specialized biotech firm, aiming to revolutionize treatment for conditions like myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) through its innovative delivery technology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 52.4M | — |
| EPS | -0.96 | -1.30 | -3.37 | -3.47 | — | -3.26 | -3.57 | -3.34 | — |
| Shares | 186.7M | 186.7M | 102.3M | 165.0M | -11.7% | 186.7M | — | — | — |
| Debt | 30.5M | 27.4M | 24.0M | 169.2M | 77.1% | 233.3M | — | — | — |
| Equity | 252.4M | 91.3M | 629.8M | 972.1M | 56.8% | — | — | — | — |
| Op CF | -153.6M | -188.2M | -292.4M | -403.2M | — | -477.8M | — | — | — |
| Inv CF | 87.2M | 83.3M | -204.1M | -28.8M | — | — | — | — | — |
| Fin CF | 37.4M | 54.3M | 809.9M | 890.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DYN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc.(you) | $4.7B | 13 | Strong Sell |
| CELC | Celcuity Inc. | $4.3B | 10 | Strong Sell |
| COGT | Cogent Biosciences, Inc. | $6.0B | 12 | Strong Sell |
| RCUS | Arcus Biosciences, Inc. | $3.7B | 14 | Strong Sell |
| GPCR | Structure Therapeutics Inc. | $3.4B | 13 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| ERAS | Erasca, Inc. | $6.3B | 14 | Strong Sell |
| BEAM | Beam Therapeutics Inc. | $3.0B | 13 | Strong Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
| PBLS | Parabilis Medicines, Inc. | $4.8B | 2 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%